Antitumor immunity induced by antibody-based natural killer cell engager therapeutics armed with not-alpha IL-2 variant

Harnessing innate immunity is emerging as a promising therapeutic approach in cancer. We report here the design of tetraspecific molecules engaging natural killer (NK) cell-activating receptors NKp46 and CD16a, the β-chain of the interleukin-2 receptor (IL-2R), and a tumor-associated antigen (TAA)....

Descripción completa

Detalles Bibliográficos
Autores principales: Demaria, Olivier, Gauthier, Laurent, Vetizou, Marie, Blanchard Alvarez, Audrey, Vagne, Constance, Habif, Guillaume, Batista, Luciana, Baron, William, Belaïd, Nourhène, Girard-Madoux, Mathilde, Cesari, Cedric, Caratini, Melody, Bosco, Frédéric, Benac, Olivier, Lopez, Julie, Fenis, Aurore, Galluso, Justine, Trichard, Sylvia, Carrette, Barbara, Carrette, Florent, Maguer, Aurélie, Jaubert, Solène, Sansaloni, Audrey, Letay-Drouet, Robin, Kosthowa, Camille, Lovera, Naouel, Dujardin, Arnaud, Chanuc, Fabien, Le Van, Mélanie, Bokobza, Sivan, Jarmuzynski, Nicolas, Fos, Camille, Gourdin, Nicolas, Remark, Romain, Lechevallier, Eric, Fakhry, Nicolas, Salas, Sébastien, Deville, Jean-Laurent, Le Grand, Roger, Bonnafous, Cécile, Vollmy, Lukas, Represa, Agnès, Carpentier, Sabrina, Rossi, Benjamin, Morel, Ariane, Cornen, Stéphanie, Perrot, Ivan, Morel, Yannis, Vivier, Eric
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9589122/
https://www.ncbi.nlm.nih.gov/pubmed/36260981
http://dx.doi.org/10.1016/j.xcrm.2022.100783

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9589122/
https://www.ncbi.nlm.nih.gov/pubmed/36260981
http://dx.doi.org/10.1016/j.xcrm.2022.100783

Ejemplares similares